This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    25/03/15

    EU approves Saxenda (liraglutide 3 mg) for Obesity-Novo Nordisk

    Novo Nordisk has announced that the European Commission has granted marketing authorisation for Saxenda (liraglutide 3 mg) for the treatment...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/01/14

    Novo Nordisk files liraglutide at FDA and EMA for treatment of Obesity

    Novo Nordisk has announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue,...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    24/12/14

    FDA approves Saxenda for Obesity- Novo Nordisk

    The FDA has approved the New Drug Application (NDA) for Saxenda (liraglutide 3 mg), from Novo Nordisk, the first once-daily...

    Journals
    Journal
    18/07/18

    Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery.

    We sought to determine the efficacy of high-dose liraglutide (3.0 mg once daily) in patients with prior bariatric surgery.

    • Source: Obesity Surgery
    Journals
    Journal
    01/03/19

    Interaction of obesity and atrial fibrillation: an overview of pathophysiology and clinical management.

    Areas covered: We will briefly discuss the obesity paradox and its mechanisms regarding cardiac and hemodynamic function changes.

    • Source: Expert Review of Cardiovascular Therapy
    African american mid adult female nurse using smart phone while holding clipboard in hospital
    Insight
    05/04/19

    Part Two - New hopes for treatment in the global obesity epidemic

    Take a look at a series of drug options and their effectiveness as treatments for obesity, as well as their ability to tackle diabetes and cardiovascular disease.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    03/06/16

    Post hoc analysis of phase IIIa SCALE study of Saxenda (liraglutide) in treatment of Obesity- Novo Nordisk

    Data from a post hoc analysis of the three-year part of the phase IIIa SCALE™ (Satiety and Clinical Adiposity –...

    African american mid adult female nurse using smart phone while holding clipboard in hospital
    Insight
    12/04/19

    Part Three - Next generation obesity therapies

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    16/05/14

    Successful Phase III SCALET trial for liraglutide for Obesity treatment - Novo Nordisk

    Results from the SCALET Obesity and Pre-diabetes phase IIIa trial will be presented on 16 May, 2014 for the first...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    04/05/16

    Positive results from SCALE phase III trials for Saxenda (liraglutide) in obesity- Novo Nordisk

    Pooled post-hoc analysis results from the SCALE Obesity and Prediabetes, and SCALE Diabetes trials demonstrated that at 56 weeks, people...

    See more